WO2010007318A3 - NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET - Google Patents

NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET Download PDF

Info

Publication number
WO2010007318A3
WO2010007318A3 PCT/FR2009/051408 FR2009051408W WO2010007318A3 WO 2010007318 A3 WO2010007318 A3 WO 2010007318A3 FR 2009051408 W FR2009051408 W FR 2009051408W WO 2010007318 A3 WO2010007318 A3 WO 2010007318A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazo
production
application
pharmaceutical compositions
met inhibitors
Prior art date
Application number
PCT/FR2009/051408
Other languages
English (en)
Other versions
WO2010007318A2 (fr
Inventor
Eric Bacque
Dominique Damour
Conception Nemececk
Patrick Nemececk
Laurent Schio
Sylvie Wentzler
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40352183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010007318(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN200980136540XA priority Critical patent/CN102159577A/zh
Priority to MX2011000670A priority patent/MX2011000670A/es
Priority to EP09737062A priority patent/EP2318414A2/fr
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to JP2011517980A priority patent/JP2011528339A/ja
Priority to BRPI0915920-7A priority patent/BRPI0915920A2/pt
Priority to EA201170224A priority patent/EA201170224A1/ru
Priority to AU2009272518A priority patent/AU2009272518A1/en
Priority to CA2730964A priority patent/CA2730964A1/fr
Publication of WO2010007318A2 publication Critical patent/WO2010007318A2/fr
Publication of WO2010007318A3 publication Critical patent/WO2010007318A3/fr
Priority to TNP2010000619A priority patent/TN2010000619A1/fr
Priority to IL210708A priority patent/IL210708A0/en
Priority to US13/007,830 priority patent/US20110263593A1/en
Priority to ZA2011/00428A priority patent/ZA201100428B/en
Priority to MA33618A priority patent/MA32564B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne les nouveaux produits de formule (I): dans laquelle : n = 0,1 ou 2; X représente H, HaI ou alk; R représente H, NH2, NHaIk, N(alk)2; Ra représente H; HaI; -O-cycloalkyle; -O-alkyle, -O-aryle; -O-hétéroaryle; - NRd(cycloalkyle); -NRd(alkyle); -NRd(aryle); -NRd(hétéroaryle); alkyle; cycloalkyle; hétérocycloalkyle; aryle ou hétéroaryle; tous éventuellement substitués; Rb représente H, Rc, -COORc-CO-Rc ou -CO-NRcRd; avec Rc représente alkyle, cycloalkyle, hétérocycloalkyle, aryle et hétéroaryle, tous éventuellement substitués; Rd représente H, alk ou cycloalkyle; ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments notamment comme inhibiteurs de MET.
PCT/FR2009/051408 2008-07-18 2009-07-16 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET WO2010007318A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2730964A CA2730964A1 (fr) 2008-07-18 2009-07-16 Nouveaux derives imidazo[1,2-a]pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
BRPI0915920-7A BRPI0915920A2 (pt) 2008-07-18 2009-07-16 derivados imidazo [1,2-a]pirimidina, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e nova utilização notadamente com inibidores de met
MX2011000670A MX2011000670A (es) 2008-07-18 2009-07-16 Nuevos derivados de imidazo [1, 2-a] pirimidina, su procedimiento de preparación, su uso como medicamentos, composiciones farmacéuticas y nuevo uso particularmente como inhibidores de met.
EP09737062A EP2318414A2 (fr) 2008-07-18 2009-07-16 Derives imidazo [1,2-a] pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation comme inhibiteurs de met
AU2009272518A AU2009272518A1 (en) 2008-07-18 2009-07-16 Imidazo [1, 2-a] pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as MET inhibitors
JP2011517980A JP2011528339A (ja) 2008-07-18 2009-07-16 イミダゾ［１，２−ａ］ピリミジン誘導体、この調製方法、薬剤としてのこの適用、医薬組成物、およびＭＥＴ阻害剤としてのこの使用
EA201170224A EA201170224A1 (ru) 2008-07-18 2009-07-16 Новые производные имидазо[1,2-a]пиримидинов, способ их получения, их применение в качестве лекарственных средств, фармацевтические композиции и новое применение, в частности, в качестве ингибиторов мет
CN200980136540XA CN102159577A (zh) 2008-07-18 2009-07-16 咪唑并[1,2-a]嘧啶衍生物，其制备方法，其作为药物、药物组合物的应用以及作为MET抑制剂的用途
TNP2010000619A TN2010000619A1 (fr) 2009-07-16 2010-12-29 NOUVEAUX DERIVES IMIDAZO [1,2-a] PYRIMIDINE LEUR PROCEDE DE PREPARATION LEUR APPLICATION A TITRE DE MEDICAMENTS COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
ZA2011/00428A ZA201100428B (en) 2008-07-18 2011-01-17 Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
US13/007,830 US20110263593A1 (en) 2008-07-18 2011-01-17 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
IL210708A IL210708A0 (en) 2008-07-18 2011-01-17 Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
MA33618A MA32564B1 (fr) 2008-07-18 2011-02-15 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0804086 2008-07-18
FR0804086A FR2933982A1 (fr) 2008-07-18 2008-07-18 Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/007,830 Continuation US20110263593A1 (en) 2008-07-18 2011-01-17 NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS

Publications (2)

Publication Number Publication Date
WO2010007318A2 WO2010007318A2 (fr) 2010-01-21
WO2010007318A3 true WO2010007318A3 (fr) 2010-04-08

Family

ID=40352183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/051408 WO2010007318A2 (fr) 2008-07-18 2009-07-16 NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET

Country Status (26)

Country Link
US (1) US20110263593A1 (fr)
EP (1) EP2318414A2 (fr)
JP (1) JP2011528339A (fr)
KR (1) KR20110043680A (fr)
CN (1) CN102159577A (fr)
AR (1) AR072820A1 (fr)
AU (1) AU2009272518A1 (fr)
BR (1) BRPI0915920A2 (fr)
CA (1) CA2730964A1 (fr)
CL (1) CL2011000118A1 (fr)
CO (1) CO6341634A2 (fr)
CR (1) CR20110031A (fr)
DO (1) DOP2011000019A (fr)
EA (1) EA201170224A1 (fr)
EC (1) ECSP11010765A (fr)
FR (1) FR2933982A1 (fr)
IL (1) IL210708A0 (fr)
MA (1) MA32564B1 (fr)
MX (1) MX2011000670A (fr)
NI (1) NI201100020A (fr)
PE (1) PE20110584A1 (fr)
SV (1) SV2011003811A (fr)
TW (1) TW201011025A (fr)
UY (1) UY31998A (fr)
WO (1) WO2010007318A2 (fr)
ZA (1) ZA201100428B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011121223A1 (fr) 2010-03-30 2011-10-06 Sanofi-Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
WO2019099578A1 (fr) 2017-11-14 2019-05-23 Chidren's Medical Center Corporation Utilisation d'imidazopyrimidine pour moduler une réponse immunitaire humaine
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2785157A (en) * 1952-11-05 1957-03-12 Eastman Kodak Co Benzothiazoleazoaniline compounds
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
US20030153568A1 (en) * 2000-02-07 2003-08-14 Basf Aktiengesellschaft Ludwigshafen, Germany Benzothiazole derivatives
WO2006038001A1 (fr) * 2004-10-06 2006-04-13 Celltech R & D Limited Derives d’aminopyrimidine en tant qu’inhibiteurs de la jnk
EP1674466A1 (fr) * 2004-12-27 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2-6-disubstitues utiles comme des inhibiteurs de la proteine kinase
WO2008064157A1 (fr) * 2006-11-22 2008-05-29 Incyte Corporation Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001454A1 (fr) * 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques
CA2553433A1 (fr) * 2004-01-23 2005-08-11 Amgen Inc. Composes de quinoleine, de quinazoline, de pyridine et de pyrimidine et utilisations connexes pour traiter l'inflammation, l'angiogenese et le cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2785157A (en) * 1952-11-05 1957-03-12 Eastman Kodak Co Benzothiazoleazoaniline compounds
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
US20030153568A1 (en) * 2000-02-07 2003-08-14 Basf Aktiengesellschaft Ludwigshafen, Germany Benzothiazole derivatives
WO2006038001A1 (fr) * 2004-10-06 2006-04-13 Celltech R & D Limited Derives d’aminopyrimidine en tant qu’inhibiteurs de la jnk
EP1674466A1 (fr) * 2004-12-27 2006-06-28 4Sc Ag Derives benzazoles 2,5- et 2-6-disubstitues utiles comme des inhibiteurs de la proteine kinase
WO2008064157A1 (fr) * 2006-11-22 2008-05-29 Incyte Corporation Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAPKE K ET AL: "On the rhodanation of halogen substituted anilines. 24. On the organic rhodan compounds", DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 22, no. 6, 1 May 1967 (1967-05-01), pages 229 - 233, XP009128816, ISSN: 0031-7144 *
VARA PRASAD J V N ET AL: "Thiocyanation of alkylanilines. A simple and efficient synthesis of thiosulfonates containing 2-aminobenzothiazole", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 21, 1 May 2000 (2000-05-01), pages 4065 - 4068, XP004204495, ISSN: 0040-4039 *

Also Published As

Publication number Publication date
UY31998A (es) 2010-02-26
KR20110043680A (ko) 2011-04-27
BRPI0915920A2 (pt) 2018-07-10
JP2011528339A (ja) 2011-11-17
EP2318414A2 (fr) 2011-05-11
SV2011003811A (es) 2011-04-29
MA32564B1 (fr) 2011-08-01
ZA201100428B (en) 2012-03-28
NI201100020A (es) 2011-07-21
CN102159577A (zh) 2011-08-17
US20110263593A1 (en) 2011-10-27
CL2011000118A1 (es) 2011-07-15
AU2009272518A1 (en) 2010-01-21
WO2010007318A2 (fr) 2010-01-21
TW201011025A (en) 2010-03-16
FR2933982A1 (fr) 2010-01-22
CO6341634A2 (es) 2011-11-21
CR20110031A (es) 2011-03-14
AR072820A1 (es) 2010-09-22
IL210708A0 (en) 2011-03-31
CA2730964A1 (fr) 2010-01-21
ECSP11010765A (es) 2011-02-28
MX2011000670A (es) 2011-04-11
DOP2011000019A (es) 2011-02-15
EA201170224A1 (ru) 2011-08-30
PE20110584A1 (es) 2011-09-10

Similar Documents

Publication Publication Date Title
WO2010007318A3 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
EA201170223A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
SI1966208T1 (sl) (1-aza-biciklo(3.3.1)non-4-il)-(5-(1H-indol-5-il)-heteroaril)-amini kot holinergični ligandi n-AChR za zdravljenje psihotičnih in nevrodegenerativnih motenj
WO2007058832A3 (fr) INHIBITEURS DES KINASES Tec
WO2012044727A3 (fr) Procédé de fabrication de dérivés de pyrimidine
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
WO2007083017A3 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
WO2004073595A3 (fr) Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2011047055A3 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
WO2013024358A3 (fr) Composés amines hétérocycliques substitués comme inhibiteurs de la protéine de transfert d'ester cholesterylique (cetp)
WO2009106751A3 (fr) Dérivés de n-heterocyclique-6-heterocyclique-imidazo[1,2- a]pyridiνe-2-carb0xamides, leur préparation et leur application en thérapeutique
WO2007026041A3 (fr) Composes quinoniques antitumoraux et leurs derives, procede d'obtention de ceux-ci et applications correspondantes
WO2008090200A3 (fr) Dérivés de 2- piperazin-1-yl-3h-imidazo[4,5-b]pyridine
WO2012136356A8 (fr) Dérivés de la 6,7-dihydro-[1,3,4] thiadiazolo-[3,2-a][1,3] diazépine et compositions pharmaceutiques les contenant en tant qu'agent hypnotique ou anesthésique et procédé pour leur préparation
WO2009101432A3 (fr) Procédé de préparation de dérivés de pyridone 226
TN2010000619A1 (fr) NOUVEAUX DERIVES IMIDAZO [1,2-a] PYRIMIDINE LEUR PROCEDE DE PREPARATION LEUR APPLICATION A TITRE DE MEDICAMENTS COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
WO2018109496A3 (fr) Acides aminés non naturels
TH133827B (th) ทริปโตไลด์โพรดรักชนิดใหม่
TH105084B (th) เกลือจำเพาะ, รูปแบบแอนไฮดรัสและรูปแบบที่เป็นผลึกของอนุพันธ์ไดไฮโดรพ์เทอริไดโอน
TH155337A (th) เกลือฟีโนไธอะซีนไดอะมิเนียมและการใช้เกลือดังกล่าว phenothiazine diaminium salts and their use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980136540.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09737062

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 177/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2730964

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011517980

Country of ref document: JP

Kind code of ref document: A

Ref document number: 0123011

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2011010106

Country of ref document: EG

Ref document number: 000049-2011

Country of ref document: PE

Ref document number: CR2011-000031

Country of ref document: CR

Ref document number: 2009737062

Country of ref document: EP

Ref document number: MX/A/2011/000670

Country of ref document: MX

Ref document number: 12011500120

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011000118

Country of ref document: CL

Ref document number: 590582

Country of ref document: NZ

Ref document number: 11004605

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009272518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2011000081

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2009272518

Country of ref document: AU

Date of ref document: 20090716

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117003698

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201170224

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201101876

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0915920

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110117